Abstract

The kidney is a major clearance organ of the body and is responsible for the elimination of many xenobiotics and prescription drugs. With its multitude of uptake and efflux transporters and metabolizing enzymes, the proximal tubule cell (PTC) in the nephron plays a key role in the disposition of xenobiotics and is also a primary site for toxicity. In this minireview, we first provide an overview of the major transporters and metabolizing enzymes in the PTCs responsible for biotransformation and disposition of drugs. Next, we discuss different cell sources that have been used to model PTCs in vitro, their pros and cons, and their characterization. As current technology is inadequate to evaluate reliably drug disposition and toxicity in the kidney, we then discuss recent advancements in kidney microphysiological systems (MPS) and the need to develop robust in vitro platforms that could be routinely used by pharmaceutical companies to screen compounds. Finally, we discuss the new and exciting field of stem cell-derived kidney models as potential cell sources for future kidney MPS. Given the push from both regulatory agencies and pharmaceutical companies to use more predictive "human-like" in vitro systems in the early stages of drug development to reduce attrition, these emerging models have the potential to be a game changer and may revolutionize how renal disposition and kidney toxicity in drug discovery are evaluated in the future.

Highlights

  • The kidneys perform essential functions in humans by maintaining the composition of blood and its pH; preventing the buildup of waste products; and keeping levels of electrolytes, such as sodium, potassium, and phosphate, stable

  • Evaluation of the mechanisms involved in the elimination of drugs and other exogenous and endogenous molecules can provide valuable understanding of their clearance, the potential for drug-drug interactions (DDIs), the potential for development of kidney and other organ toxicity, and on the effect of the elimination of an investigational drug on its pharmacokinetics (PK) in patients with compromised kidney functions

  • Accumulating evidence indicates an important role of the kidney in the metabolism, transport, and clearance of xenobiotics, proteins, hormones, and endogenous compounds; there has been accelerated growth in the past decade in the development of technologies to investigate the disposition of new chemical entities (NCE) targeted to treat human diseases and potential for toxicities

Read more

Summary

Introduction

The kidneys perform essential functions in humans by maintaining the composition of blood and its pH; preventing the buildup of waste products; and keeping levels of electrolytes, such as sodium, potassium, and phosphate, stable. Evaluation of the mechanisms involved in the elimination of drugs and other exogenous and endogenous molecules can provide valuable understanding of their clearance, the potential for drug-drug interactions (DDIs), the potential for development of kidney and other organ toxicity, and on the effect of the elimination of an investigational drug on its pharmacokinetics (PK) in patients with compromised kidney functions. Metabolizing enzymes in the kidneys play an important role in the clearance of xenobiotics and endogenous compounds (Lash, 1994; Lock and Reed, 1998; Lohr et al, 1998; Knights et al, 2013). Accumulating evidence indicates an important role of the kidney in the metabolism, transport, and clearance of xenobiotics, proteins, hormones, and endogenous compounds; there has been accelerated growth in the past decade in the development of technologies to investigate the disposition of NCEs targeted to treat human diseases and potential for toxicities. List of drug-metabolizing enzymes commonly associated with biotransformation of drugs and xenobiotics in the kidney (Lash, 1994; Lock and Reed, 1998; Lohr et al., 1998; Knights et al, 2013)

Glutathione peroxidase
Apical Apical Apical Apical Apical
Common Sources of Kidney Cells
Importance of Fluid Shear Stress for KPT Cells
Kidney MPS Technologies for Drug Discovery
Findings
Current Challenges and Future Perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call